Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Journal of Clinical Investigation

Volumn 123, Issue 10, 2013, Pages 4111-4120

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ASIMADOLINE; AST 120; CROMOGLYCATE DISODIUM; DARIFENACIN; ELOBIXIBAT; FLUTICASONE; GASTROINTESTINAL AGENT; GLUTAMINE; KETOTIFEN; LUBIPROSTONE; MESALAZINE; NALOXEGOL; NALOXONE; NALTREXONE; NARONAPRIDE; OTILONIUM BROMIDE; PEPPERMINT OIL; PINAVERIUM; PLECANATIDE; PRUCALOPRIDE; RAMOSETRON; SOLIFENACIN; TAPENTADOL; TOFISOPAM; TRIMEBUTINE; ULIMORELIN; UNINDEXED DRUG; VELUSETRAG;

CHRONIC DIARRHEA; CLINICAL TRIAL (TOPIC); COLON MOTILITY; CONSTIPATION; ESOPHAGITIS; ESOPHAGUS ACHALASIA; ESOPHAGUS DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; STOMACH PARESIS; VISCERAL PAIN;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIARRHEA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; NEUROTRANSMITTER AGENTS; PAIN PERCEPTION; PARESIS; SENSORY SYSTEM AGENTS;

EID: 84885080634     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70837     Document Type: Review

References (120)

1. Cho YK, et al. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig Dis Sci. 2013;58(4):1035-1041.
2. Kuo P, Holloway RH. Beyond acid suppression: new pharmacologic approaches for treatment of GERD. Curr Gastroenterol Rep. 2010;12(3):175-180.
3. Rohof WO, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther. 2012;35(10):1231-1242.
4. Fox M, Sweis R, Wong T, Anggiansah A. Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases. Neurogastroenterol Motil. 2007;19(10):798-803.
5. Vanuytsel T, et al. Botulinum toxin reduces dysphagia in patients with non-achalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol. 2013; pii: S1542-3565 (13) 00461-8.
6. Hershcovici T, Achem SR, Jha LK, Fass R. Systematic review: the treatment of noncardiac chest pain. Aliment Pharmacol Ther. 2012;35(1):5-14.
7. Bredenoord AJ. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. Am J Gastroenterol. 2012;107(1):8-15.
8. Peles S, et al. Differential effects of transient receptor vanilloid one (TRPV1) antagonists in acid-induced excitation of esophageal vagal afferent fibers of rats. Neuroscience. 2009;161(2):515-525.
9. Krarup AL, et al. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scand J Gastroenterol. 2013;48(3):274-284.
10. Prasad GA, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2009;7(10):1055-1061.
11. Podas T, Eaden J, Mayberry M, Mayberry J. Achalasia: a critical review of epidemiological studies. Am J Gastroenterol. 1998;93(12):2345-2347.
12. Dellon ES, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679-692.
13. Katzka DA, Loftus EV Jr, Camilleri M. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases. Clin Pharmacol Ther. 2012;92(3):306-320.
14. Dent G, et al. Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am J Respir Crit Care Med. 2004;169(10):1110-1117.
15. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18-37.
16. Sanger GJ, Wang Y, Hobson A, Broad J. Motilin: Toward a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists [published online ahead of print November 28, 2012]. doi:10. 1111/bph. 12075.
17. Ejskjaer N, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther. 2009;29(11):1179-1187.
18. Ejskjaer N, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebocontrolled study. Neurogastroenterol Motil. 2010;22(10):1069-e281.
19. Wo JM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting-randomised clinical study subset data. Aliment Pharmacol Ther. 2011;33(6):679-688.
20. Ang D, et al. Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. Neurogastroenterol Motil. 2009;21(5):528-533.
21. McCallum R, et al. TZP-102, ghrelin agonist phase 2 data: the improvement in symptoms of gastroparesis (nausea, early satiety, bloating and abdominal pain) significantly correlated with patient rating of overall treatment effect. Gastroenterology. 2011;140(5):S807.
22. Ejskjaer N, et al. A phase 2a, randomized, doubleblind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25(2):e140-e150.
23. McCallum RW, et al. TZP-102-CL-G003 phase 2b study results: oral TZP-102 once daily for 12 weeks in patients with diabetic gastroparesis. Gastroenterology. 2013;144(5 suppl 1):S160-S161.
24. Shin A, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013;36(1):41-48.
25. Shin A, et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol. 2013; pii: S1542-3565 (13) 00578-8.
26. Leming S, et al. GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil. 2011;23(10):958-e410.
27. Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol. 2012;167(4):763-774.
28. Dukes GE, et al. Safety/tolerability, pharmacokinetics (PK), and effect on gastric emptying (GE) with 14-days repeat oral dosing of the motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterol Motil. 2010;22:14-15.
29. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7):707-717.
30. Sciarretta G, et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut. 1987;28(8):970-975.
31. Brydon WG, Nyhlin H, Eastwood MA, Merrick MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol. 1996;8(2):117-123.
32. Wong BS, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10(9):1009-1015. e3.
33. Shin A, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013; pii: S1542-3565 (13) 00579-X.
34. Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
35. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28-35.
36. Hoffman JM, et al. Activation of colonic mucosal 5-HT (4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology. 2012;142(4):844-854.
37. Freiman J, et al. LX1031: inhibition of 5-HT synthesis as a new target in the management of irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2009;21(9):250.
38. Brown PM, et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology. 2011;141(2):507-516.
39. Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology. 2007;15(1):5-9.
40. Hirata T, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008;20(5):557-565.
41. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrheapredominant irritable bowel syndrome. Digestion. 2008;77(3-4):225-235.
42. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebocontrolled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008;43(10):1202-1211.
43. Lee KJ, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098- 1104.
44. Bharucha AE, Ravi K, Zinsmeister AR. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010;299(1):G215-G219.
45. Czimmer J, Süto G, Király A, Mózsik G. Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. J Physiol Paris. 2001;95(1-6):153-156.
46. Krueger D, et al. Effect of hyoscine butylbromide (Buscopan) on cholinergic pathways in the human intestine. Neurogastroenterol Motil. 2013;25(8):e530-e539.
47. Clavé P, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(4):432-442.
48. Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(4):402-410.
49. Fukushima Y, Suzuki H, Matsuzaki J, Kiyosue A, Hibi T. Efficacy of solifenacin on irritable bowel syndrome with diarrhea: open-label prospective pilot trial. J Neurogastroenterol Motil. 2012;18(3):317-323.
50. Anderson K, Fischer L. Prevention of GI absorption of bacterial toxins: an in vitro evaluation of the potential for prophylactic use of a novel oral adsorbent (AST-120). Gastroenterology. 2008;134(4 suppl 1):A-675.
51. Tack JF, Miner PB Jr, Fischer L, Harris MS. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;34(8):868-877.
52. Lobo B, et al. Clinical benefit in IBS after disodium cromoglycate involves mast cell-mediated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa. Gastroenterology. 2009;136(suppl 1):156.
53. Lobo B, et al. Clinical improvement in IBS after disodium cromoglycate involves mast cell-mediated toll-like receptor signaling downregulation. Gastroenterology. 2011;140(suppl 1):499-500.
54. Leri O, et al. Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate. Inflammopharmacology. 1997;5(2):153-158.
55. Klooker TK, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59(9):1213-1221.
56. Corinaldesi R, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009;30(3):245-252.
57. Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(3):374-383.
58. Dorofeyev AE, Kiriyan EA, Vasilenko IV, Rassokhina OA, Elin AF. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol. 2011;4:141-153.
59. Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome - a pilot study. Scand J Gastroenterol. 2012;47(10):1159-1164.
60. Leventer SM, et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol. 2004;99(suppl 5):S279.
61. Leventer SM, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27(2):197-206.
62. Delvaux M, Beck A, Jacob J, Bouzamondo H, Weber FT, Frexinos J. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(2):237-246.
63. Delgado-Aros S, et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol. 2003;284(4):G558-G566.
64. Mangel AW, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28(2):239-249.
65. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-G785.
66. Basra S, Verne GN, Zhou Q. Randomized placebocontrolled trial of glutamine for the treatment of diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2013;144(5 suppl 1):S160.
67. Nullens S, et al. Regional colon transit in patients with dyssynergic defecation or slow transit in patients with constipation. Gut. 2012;61(8):1132-1139.
68. Cinca R, Chera D, Gruss HJ, Halphen M. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in a controlled environment. Aliment Pharmacol Ther. 2013;37(9):876-886.
69. Duboc H, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24(6):513-520.
70. Demaeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99-112.
71. Camilleri M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin Pharmacol Ther. 2012;91(1):44-59.
72. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344-2354.
73. Goldberg M, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, doubleblind, placebo-controlled, dose-response study. Aliment Pharmacol Ther. 2010;32(9):1102-1112.
74. Donowitz M, et al. NHERF family and NHE3 regulation. J Physiol. 2005;567(pt 1):3-11.
75. Shailubhai K, Talluto C, Comiskey S, Foss JA, Joslyn A, Jacob G. Phase II clinical evaluation of SP-304, a guanylate cyclase-C agonist, for treatment of chronic constipation. Am J Gastroenterol. 2010;105(10):S487-S488.
76. Miner P, et al. Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12-week, multi-center trial. Gastroenterology. 2013;144(5 suppl 1):S163.
77. Wong B, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106(12):2154-2164.
78. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011;106(10):1803-1812.
79. Buchwald H, Rudser KD, Williams SE, Michalek VN, Vagasky J, Connett JE. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg. 2010;251(6):1034-1040.
80. Rang HP, Dale MM, Ritter JM. Analgesic drugs. Pharmacology. 1999;13(2):579-603.
81. De Schepper HU, et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16(4):383-394.
82. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A suppl):11S-18S.
83. Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin. 2010;26(7):1677-1684.
84. Afilalo M, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: results of a randomized, double-blind, placeboand active-controlled phase 3 study. Clin Drug Investig. 2010;30(8):489-505.
85. Buynak R, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother. 2010;11(11):1787-1804.
86. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10(2):135-144.
87. Vondrackova D, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144-1154.
88. Meissner W, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56-64.
89. Sandner-Kiesling A, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64(6):763-774.
90. Camilleri M. Invited Review: Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835-842.
91. Paulson DM, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction. a 21-day treatment-randomized clinical trial. J Pain. 2005;6(3):184-192.
92. Webster L, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebocontrolled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137(2):428-440.
93. Jansen JP, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):185-193.
94. Irving G, et al. Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):175-184.
95. Neumann TA, et al. Clinical investigation of oral NKTR-118 as a selective oral peripheral opioid antagonist. Proceedings of the 18th Annual Clinical Meeting of the American Academy of Pain Management. Las Vegas, Nevada, USA. September 27. 30, 2007, abstract 27.
96. Chey WD, et al. Efficacy and safety of naloxegol in patients with opioid-induced constipation: results from 2 prospective, randomized, controlled trials. Gastroenterology. 2013;144(5 suppl 1):S159-S160.
97. Armstrong SR, et al. The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(6):471-478.
98. Vickery R, Li Y-P, Kohler R, Webster L, Singla N, Daniels O. TD-1211 demonstrates constipation-relieving effects, including decrease in rescue laxative use, in patients with opioid-induced constipation. Am J Gastroenterol. 2011;106(10 suppl 2):S513-S514.
99. Vickery RG, Li Y-P, Schwertschlag U, Singla NK, Webster L, Canafax DM. TD-1211 phase 2b study demonstrates increased bowel movement frequency and constipation-related symptom improvement in patients with opioid induced constipation. Gastroenterology. 2013;144(5 suppl 1):S159.
100. McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med. 2008;9(6):634-659.
101. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage. 2007;34(5):547-565.
102. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912-2921.
103. Cryer BL, et al. A phase 3, randomized, doubleblind, placebo-controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain. Gastroenterology. 2010;138(suppl 1):S129.
104. Jamal MM, Mareya SM, Woldegeorgis F, Joswick TR, Ueno R. Lubiprostone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3, randomized, double-blind, placebo-controlled clinical trial. Gastroenterology. 2012;142(suppl 1):S144-S145.
105. Cuppoletti J, Chakrabarti J, Tewari K, Malinowska DH. Methadone but not morphine inhibits lubiprostonestimulated Cl-currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl-currents. Cell Biochem Biophys. 2013;66(5):53-63.
106. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011; (8): CD003460.
107. Parkman HP, et al. Nortriptyline for idiopathic gastroparesis: a multicenter, randomized, doublemasked, placebo-controlled trial (NORIG). Gastroenterology. 2013;144(5 suppl 1):S1.
108. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil. 2013;25(6):453-457.
109. Talley NJ, Choung RS, Camilleri M, Dierkhising RA, Zinsmeister AR. Asimadoline, a κ-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther. 2008;27(11):1122-1131.
110. Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther. 2009;29(2):198-206.
111. Camilleri M, et al. Effect of a glucagon-like peptide 1 analog, ROSE-010, on gastrointestinal motor functions in females with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(1):G120-G128.
112. van Wanrooij S, Wouters MM, Van Oudenhove L, Vermeire S, Rutgeerts PJ, Boeckxstaens GE. Effect of the H1-receptor antagonist ebastin on visceral perception and clinical symptoms in IBS. Gastroenterology. 2013;144(5 suppl 1):S160.
113. Tack JF, et al. Efficacy of ibodutant, a selective antagonist of neurokinin 2 receptors, in irritable bowel syndrome with diarrhea (IBS-D): the results of a double-blind, randomized, placebo-controlled, parallel-group phase II study. Gastroenterology. 2013;144(5 suppl 1):S92-S93.
114. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2003;1(4):264-272.
115. Tack J, Janssen P, Masaoka T, Farre R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10(11):1239-1245.
116. Miwa H, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009;104(11):2779-2787.
117. Tack J, et al. A dose-ranging, placebo-controlled pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009;21(3):272-280.
118. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for mealrelated symptoms of functional dyspepsia. Gut. 2012;61(6):821-828.
119. Kusunoki H, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540-545.
120. Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2013;14(9):1151-1160.